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710Objective: Current pulsatile ventricular assist devices operate asynchronous with the left ventricle in fixed-rate
or fill-to-empty modes because electrocardiogram-triggered modes have been abandoned. We hypothesize that
varying the ejection delay in the synchronized mode yields more precise control of hemodynamics and left ven-
tricular loading. This allows for a refined management that may be clinically beneficial.
Methods: Eight sheep received a Thoratec paracorporeal ventricular assist device (Thoratec Corp, Pleasanton,
Calif) via ventriculo-aortic cannulation. Left ventricular pressure and volume, aortic pressure, pulmonary flow,
pump chamber pressure, and pump inflow and outflow were recorded. The pump was driven by a clinical pneu-
matic drive unit (Medos Medizintechnik AG, Stolberg, Germany) synchronously with the native R-wave. The
start of pump ejection was delayed between 0% and 100% of the cardiac period in 10% increments. For each of
these delays, hemodynamic variables were compared with baseline data using paired t tests.
Results: The location of the minimum of stroke work was observed at a delay of 10% (soon after aortic valve
opening), resulting in a median of 43% reduction in strokework compared with baseline. Maximum strokework
occurred at a median delay of 70% with a median stroke work increase of 11% above baseline. Left ventricular
volume unloading expressed by end-diastolic volume was most pronounced for copulsation (delay 0%).
Conclusions: The timing of pump ejection in synchronized mode yields control over left ventricular energetics
and can be a method to achieve gradual reloading of a recoverable left ventricle. The traditionally suggested
counterpulsation is not optimal in ventriculo-aortic cannulation when maximum unloading is desired. (J Thorac
Cardiovasc Surg 2013;146:710-7)In selected patients with advanced heart failure, the use of
left ventricular assist devices (LVADs) has resulted in pro-
longed survival and a better quality of life.1,2 Over the
past decade, the design of LVADs intended for long-term
use has evolved from the first generation of volume-
displacement, or pulsatile, pumps to today’s smaller and
lighter continuous-flow pumps.3,4 The latter have obvious
benefits, the major one being the possibility of
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The Journal of Thoracic and Cardiovascular Surgwith continuous flowmay have a better long-term durability
and a greater patient/physician acceptability because of
their size, silent operation, and easier handling. However,
their efficacy of left ventricular unloading and right ventric-
ular afterload reduction may not be as pronounced as in the
more physiologic pulsatile LVADs.5-7 Additional benefits of
pulsatile ventricular assist devices (VADs) over continuous-
flow systems are the greater likelihood of aortic valve open-
ing6 and lower rate of gastrointestinal bleeding events.8
With both types of devices, it has been shown that ventric-
ular reverse remodeling can be induced by mechanical cir-
culatory support.9 However, it is unclear what degree and
duration of ventricular unloading would optimize left ven-
tricular recovery. Partial loading of the left ventricle (LV)
by reducing the VAD rate10 or stroke volume,11 for example,
could be used for weaning patients from a VAD, given that
the supported LV has the potential to gradually recover.
In terms of VAD cycle duration, there are 3 common op-
erating modes of a pulsatile VAD: the fixed rate, synchro-
nized to the heart rate, or the automatic mode wherein the
VAD ejection is triggered when the pump chamber is full
(recognized by a hall-effect switch).12 The latter has be-
come the standard operating mode for pulsatile VADs
once the early postoperative period has passed. However,ery c September 2013
Abbreviations and Acronyms
ECG ¼ electrocardiogram
LV ¼ left ventricle
LVAD ¼ left ventricular assist device
VAD ¼ ventricular assist device
Amacher et al Evolving Technology/Basic Sciencethe lack of synchrony between heart and pulsatile VAD
causes a fluctuation in LV load that may impede recovery
and even cause intermittent overloading.13
Therefore, we hypothesize that a synchronous mode of
operation in combination with a prescribed phase shift
(ejection delay relative to the RR duration) might be used
for stabilizing and controlling the load on the recovering
LV while maintaining perfusion. Such a control scheme
would permit gradual ‘‘reloading therapy’’ and may have
a beneficial effect on recovery rates. Although previous in-
vestigations in this matter are inconclusive,6,14-16 there has
yet to be a clinical study in which the degree of ventricular
reloading has been consistently, systematically maintained.
An optimized pulsatile VAD actuation scheme as described
would enable such a study to be performed.
In this study, we established a sheep model with pulsatile
mechanical circulatory support in a synchronized mode to
investigate the influence of phase shift on LVunloading de-
scribed by pressure, volume, stroke work, and wall stress. A
further aim of this study was to identify an optimal phase
shift in which maximal ventricular unloading is achieved
and to identify the contraindicated phase shift that risks
cardiac overload.E
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Animals
This experiment was approved by the Commission of Animal Experi-
mentation of the Canton of Bern, Switzerland (Approval No. 52/09). A par-
acorporeal ventricular assist device (Thoratec Corp, Pleasanton, Calif) was
implanted in 8 adult, female, random-bred sheep (59-83 kg).
Anesthetic Management
All animals were premedicated intramuscularly with 0.2 mg/kg of
both midazolam and methadone. General anesthesia was induced with
intravenous midazolam (0.2 mg/kg), ketamine (3.5 mg/kg), and propofol
(1-3 mg/kg). After orotracheal intubation, anesthesia was maintained with
isoflurane in oxygen (end-tidal concentration 1.6%), fentanyl (5 mg/kg bolus
and then 5-10mg/kg/h intravenously), and rocuronium (0.15-0.6mg/kg intra-
venously). The sheep were mechanically ventilated. An orogastric tube was
placed to decompress the rumen, and the rectal temperature was maintained
between 36C and 38C with a circulating warm air blanket. Severe intrao-
perative blood loss was compensated for by autologous blood transfusion
with a cell saver (AutoLog; Medtronic Inc, Minneapolis, Minn). At the end
of the experiment, the animals were euthanized under anesthesiawith a lethal
dose of intravenous potassium chloride.
Surgical Preparation
The pulsatileVADwas implanted via left lateral thoracotomy in the third
intercostal space. A dual-pressure 7F admittance catheter (Scisense Inc,The Journal of Thoracic and CaLondon, Ontario, Canada) was placed in the LV via the right carotid artery
for measuring LV pressure, LV volume, and aortic pressure. An ultrasonic
transit time flow probe (22PAU or 24PAU; Transonic Systems Inc, Ithaca,
NY) was placed around the pulmonary artery to measure total cardiac out-
put. For inflow cannulation, we inserted a modified curved 32F venous can-
nula (DLP67532, Medtronic Inc) into the left ventricular apex and
stabilized it with a double-pledged purse-string suture. A 1.27-cmpolyvinyl
chloride tubewas extendedwith a 12-mmBiplex graft (Gelweave;Vascutek
Terumo GmbH, Renfrewshire, Scotland) to form the outflow cannula,
which was cut to length during surgery. The graft was anastomosed end
to side to the proximal descending aorta because the ascending aorta cannot
be approached safely from a lateral incision in the sheep and the pulmonary
artery flow probe (mentioned earlier) interferes with a safe manipulation of
the ascending aorta. The pump was mounted in a holder by the processus
xiphoideus to allow for cannula lengths as in human cases. Ultrasonic
flow probes (11PXL, Transonic Systems Inc) were installed on the cannulas
for measuring pulsatile VAD inflow and outflow. Fluid-filled pressure
transducers (Truwave; Edwards Lifesciences LLC, Irvine, Calif) were
used to measure VAD chamber pressure, driveline air pressure, and left
atrial pressure. To measure VAD chamber pressure, a luer connector was
installed between the pump sac and the outflowvalve. All pressuremeasure-
ment devices were zeroed at atmosphere and calibrated with a handheld
piston calibrator (PXCAL, Edwards Lifesciences LLC).
Ventricular Assist Device Actuation
The pulsatile VAD was actuated using a clinical pneumatic drive unit
(Medos Medizintechnik AG, Stolberg, Germany) in external trigger
mode. To improve the quality of synchronization, an application-specific
algorithm was programmed in LabView (National Instruments, Austin,
Tex) and run in real-time on a cRIO-9074 (National Instruments) to per-
formR-wave detection.17 This algorithmwas extended with arrhythmia de-
tection such that the sensitivity of the VAD rate to disturbances could be
reduced. An analog signal to trigger VAD ejection was generated and ap-
plied to the external input of the clinical pneumatic drive unit.
The systolic and diastolic pressures were set at the beginning of each
experiment to achieve maximum VAD outflow with a 50% phase shift
and were further kept constant. The primary independent variable was
the phase shift, which is the delay between the R-wave and the onset of
the VAD systole, designated as the percentage of the actual RR duration
(thereby responding dynamically to changes in the heart rate). This defini-
tion is illustrated in Figure 1,C. For all experiments, the systolic duration of
the VAD was maintained at 35% of the current VAD cycle duration.
Measurement Protocol
At the beginning and the end of each experiment, a baseline recording
was made with the VAD off and clamped. The pulsatile VADwas then syn-
chronized to the heartbeat using the clinical pneumatic drive unit and the
synchronization algorithm described earlier. In each experiment, 10 differ-
ent phase shifts, equally spaced between 0% and 100%, were applied for 5
minutes each. This allowed the analysis of the full range of phase shift set-
tings, such that situations between the 2 extremes of co- and counterpulsa-
tion could be studied. The order of phase shift settings was randomized
before the study and different for each animal.
Pharmacologic Interventions
In all animals, the same measurement protocol was repeated 3 times un-
der different pharmacologic conditions. This allows analyzing the heart–
VAD interaction over a wider range of hemodynamic states such that the
effects observed in our data are not limited to normal hemodynamic condi-
tions. The first protocol involved baseline normotensive hemodynamics,
described earlier. For the second protocol, phenylepherine (bolus, 1.25-
2.25 mg/kg; maintenance, 0.3-0.5 mg/kg/min) was used to increase after-
load. Cardiac contractility was reduced in the third protocol using esmolol
(initial bolus, 50 mg/kg; maintenance, 5-20 mg/kg/min). The esmololrdiovascular Surgery c Volume 146, Number 3 711
FIGURE 1. A andB, The procedure of data preparation for statistical anal-
ysis is illustrated for the example of stroke work in animal number 8, proto-
col 3 (decreased contractility).The beat-to-beat variables are assigned to 1 of
10 phase shift groups according to the actual phase shift. Group 0: 0% to 5%
and 95% to 100%. Group 1: 5% to 15%. Group 2: 15% to 25%. Group 3:
25% to 35%. Group 4: 35% to 45%. Group 5: 45% to 55%. Group 6: 55%
to 65%. Group 7: 65% to 75%. Group 8: 75% to 85%. Group 9: 85% to
95%. C, The definition of phase shift with respect to the RR duration is il-
lustrated. The systolic duration of the pulsatile VAD is chosen to be constant
(35%). PS, Phase shift; RR, RR duration; SD, systolic duration.
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was achieved.
Data Processing and Statistical Analysis
Measured data were recorded using a digital acquisition system (400
Series, iWorx Systems Inc, Dover, NH). The recorded data were processed
in MATLAB (R2011b, The Mathworks Inc, Natick, Mass). When steady-
state hemodynamic conditions were achieved, the right ventricular cardiac
output as measured at the pulmonary artery was used as a measure of total
cardiac output. With the measured pulsatile VAD outflow, it was possible
to obtain an estimate of the resulting volume flow through the aortic valve.
The ratio of pulsatile VAD flow to total cardiac output was defined as the
assistance ratio. Regurgitation from the pulsatile VAD to the LV was cal-
culated as the negative portion of the flow probe data at the inlet cannula.712 The Journal of Thoracic and Cardiovascular SurgLV volume as measured by admittance was calibrated in post-processing
by matching stroke volume from the catheter to that derived from the
flow signal on the pulmonary artery (with deactivated device and clamped
cannulas). Blood conductivity was measured after each protocol and in-
cluded in the volume calculation according to Wei and colleagues’ for-
mula.18 LV stroke work was calculated for each beat as the area in the
pressure-volume plane. LV wall-stress was calculated using an ellipsoidal
approximation described previously.19 The LV wall volume required for
this method was obtained by excising the heart after euthanasia, removing
the right ventricle and atria, and submerging the remaining LV in a gradu-
ated cylinder.
An interval of 20 heartbeats without arrhythmia events was selected for
each phase shift setting for further analysis. For all the data sections chosen,
the median values were used for further analysis to minimize the variation
induced by breathing effects. These values were then assigned to 1 of 10
phase shift groups. This procedure is illustrated in Figure 1, A and B.
Statistical analyses were performed using IBM SPSS Statistics 19
(SPSS Inc, Chicago, Ill). To compare data from a specific phase shift setting
with baseline values, paired t tests were used. The significance level used
for all statistical tests performed was 5%.
RESULTS
Eight of 24 recorded data sets were excluded from this
study, leaving a total of 16 data sets from 6 animals
available for further analysis. These data sets resulted
from animals that remained in stable condition throughout
the experiment. The 2 reasons for exclusion were strongly
arrhythmic behavior and untrustworthy LV pressure record-
ings (catheter tip touches LV wall).
Pharmacologic interventions resulted in repeatable con-
ditions over the 3 different protocols applied (standard, in-
creased afterload, and decreased contractility), as illustrated
in Figure 2. Mean stroke work for the 3 protocols was 0.39 J
(standard deviation, 0.09 J), 0.5 J (0.13 J), and 0.25 J (0.08
J), respectively. Corresponding values of mean arterial pres-
sure were 57mmHg (4 mmHg), 77 mmHg (9 mmHg), and
50 mm Hg (6 mm Hg), respectively. These values represent
the physiologic response expected from the interventions
applied. The variation of heart rate (mean, 94 beats/min;
range, 84-116 beats/min), mean arterial pressure (mean,
58 mm Hg; range, 40-89 mm Hg), and cardiac output
(mean, 5.3 L/min; range, 2.7-8.3 L/min) provided a wide
range of hemodynamic conditions for consideration.
Influence of Phase Shift on Left Ventricular Volume
The phase shift was found to significantly influence the
LV volume (Figures 3 and 4). In the pressure-volume plane,
the isovolumic contraction and relaxation of the unsup-
ported ventricle (in the absence of valve leakage) are repre-
sented by vertical lines. However, in our supported sheep
hearts these phases can deviate significantly from the isovo-
lumic line and tilt leftward or rightward depending on the
phase shift. Regurgitation from the pump to the LV was
1.01 L/min (mean flow over all data analyzed) and de-
pended on the phase shift as shown in Figure 5, D, with
the highest regurgitation at phase shifts 50% to 70%.
End-diastolic volume was significantly reduced withery c September 2013
FIGURE 2. The left plot shows a representative example of LV pressure-volume loops in baseline (VAD off and clamped) from animal number 2 for the 3
different pharmacologic protocols applied (standard, increased afterload, and decreased contractility). For each of these cases, pressure-volume loops from 3
consecutive heartbeats are shown. On the right side, 2 boxplots show the response of LV stroke work and mean arterial pressure in baseline to the pharma-
cologic interventions.
Amacher et al Evolving Technology/Basic Sciencerespect to baseline for each phase shift setting (Figure 4, C).
The minimum end-diastolic volume was observed at copul-
sation (phase shift 0%).Influence of Phase Shift on Pressures
The developed LV pressure was found to significantly de-
pend on the phase shift (Figures 3 and 4, G). For the phase
shifts 0%, 10%, 20%, 70%, 80%, and 90%, an increase of
peak LV pressure above baseline was observed. Contrarily,
peak LV pressure was low when the VAD diastole occurred
during the LV systole (phase shifts 30%, 40%, 50%, and
60%). Mean left atrial pressure was significantly reduced
compared with baseline except for the phase shift 40%
(Figure 4, J). Mean arterial pressure was increased over
baseline for the phase shifts 0%, 10%, 20%, 30%, 80%,
and 90% (Figure 4, H).E
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Unloading
We identified the phase shifts 0% to 50% to have a signif-
icant impact on unloading the LV in terms of stroke work
(Figure 4, B). The phase shift 10% had the greatest reduc-
tion in median stroke work (–43%). Despite the fact that the
median value is minimal for the phase shift 10%, it was pos-
sible that the stroke work was greater than at baseline for in-
dividual cases in this phase shift.
Mean wall stress (Figure 4, D) was reduced compared
with baseline for each phase shift setting except for the
phase shifts 0%, 80%, and 90%. Peak wall stress
(Figure 4, F) was significantly greater than at baseline for
the phase shifts 80% and 90%.The Journal of Thoracic and CaDISCUSSION
We analyzed the complex interaction between a pulsatile
VAD and the LV for synchronized mechanical circulatory
support with different phase shifts (relative ejection delays)
to obtain more knowledge about the relationship between
pump timing and cardiac loading conditions in terms of vol-
umes, pressures, stroke work, and wall stress. In the data
presented, phase shift has been actively set at a desired
value using a clinical pneumatic drive unit extended with
custom-made software for improved electrocardiogram
(ECG) triggering. Ten different phase shift settings have
been applied. This allowed a detailed analysis of the result-
ing hemodynamics.
Actuating pulsatile VADs requires a number of parame-
ters that have to be set by trained personnel during assis-
tance, such as the rate, systolic duration, and filling and
ejection pressures.12,20 Earlier publications studied the
influence of selected choices for these parameters on the
coupled pulsatile VAD-cardiovascular system in silico21,22
or in vivo.16,23 Most previous research has focused on the
case of atrio-aortic cannulation, but in the clinical setting,
ventriculo-aortic cannulation has now been established for
the majority of LVADs. For the atrio-aortic configuration,
it was concluded earlier that VAD ejection should occur
soon after aortic valve closure to minimize the oxygen con-
sumption of the LV.21,22 This unloading effect was obtained
by LV preload reduction. For the atrio-aortic cannulation,
the LV is not connected directly to the VAD, and therefore
the afterload is exclusively determined by the aortic pres-
sure. For ventriculo-aortic cannulation, however, the LV
can eject in both the aorta and the pulsatile VAD. The after-
load imposed on the LV thus depends on instantaneousrdiovascular Surgery c Volume 146, Number 3 713
FIGURE 3. LV pressure-volume loops for animal number 8, protocol 3 (decreased contractility). Baseline 1 and 2 are recorded immediately before and
after applying the different VAD settings. The PV loops for the different phase shifts are ordered by increasing phase shifts from top left to bottom right. The
symbol x denotes the start of VAD systole; o denotes the start of pump filling.
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analyzed in this study.
Figure 3 shows that both the start and the end of pump
ejection influence the shape of the LV pressure-volume
loops. It can be seen that at phase shifts 39% and 49%,
the start of VAD systole stops blood ejection from the LV,
whereas at phase shifts 79%, 89%, and 99% ejection of
blood from the LV starts immediately after the VAD systole
is over. Thus, in addition to the start of pump ejection rela-
tive to the cardiac cycle, the end of pump ejection influences
LV pressure and volume.
The phase shift in ventriculo-aortic cannulation influ-
ences not only the LV pressure developed but also the frac-
tion of blood that is ejected from the LV through the aortic
valve with respect to total LV stroke volume. Because of the
controlled phase shift, different scenarios can be achieved.
For instance, the LV stroke volume and end-diastolic vol-
ume can be maximized for phase shifts between 50% and714 The Journal of Thoracic and Cardiovascular Surg70%, in which case most of the volume ejected from the
LV contributes to pulsatile VAD filling.
In another case, the end-diastolic volume can be re-
duced maximally by using co-pulsation (phase shift 0%)
because in that case pump filling occurs during LV dias-
tole and blood can flow through the LV into the pump
chamber without expanding the LV. In this case, opening
of the aortic valve is favored. This would help to prevent
cusp fusion or thrombus formation at the level of the aortic
valve.
The pulsatile VAD used contains tilting disc valves such
that moderate regurgitation over both valves cannot be
avoided completely. Previous authors have stated that pul-
satile VAD inflow regurgitation could inhibit the ventricular
reverse remodeling processes.24 The amount of regurgita-
tion depends on the pressure difference across the valve
and thus on the phase shift (Figure 5, D). By applying our
method, it would be possible to minimize regurgitation byery c September 2013
FIGURE 4. Boxplots of analyzed variables clustered according to their phase shift are shown (each box represents the median value and 25th and 75th
percentiles;þ denotes outliers). Data points are normalized by the baseline values of the individual data sets. Panel A through J show cardiac output, stroke
work, end-diastolic volume, mean wall stress, LV stroke volume, peak wall stress, peak LV pressure, mean arterial pressure, LV pressure at aortic valve
opening, and mean left atrial pressure. The outcome of the paired t test is shown below the corresponding data (o: significant decrease compared with base-
line, x: significant increase compared with baseline, no symbol: no significant difference compared with baseline). Mean left atrial pressurewas available for
only 8 different data sets. LV, Left ventricle.
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phases of the pulsatile VAD and LV.
The results presented in terms of LV pressure agree with
recently published data where a pulsatile VAD was im-
planted in a pig model.15 Both studies show that peak LV
pressure was minimized for counterpulsation (phase shifts
30% to 60%; Figure 4, G). This phenomenon can be ex-
plained by the pulsatile VAD being in its filling phase dur-
ing LV systole, and thus the LV can dump blood in the pump
chamber without developing high pressure. Nevertheless,
our results add knowledge to these findings because we
also show that minimal LV pressure does not correspond
with minimal LV load in terms of LV stroke work.The Journal of Thoracic and CaAs is known from intra-aortic balloon counterpulsation,
the end-diastolic arterial pressure, or pressure at aortic valve
opening, is an important determinant of cardiac load. Our
results (Figure 4, I) indicate that this pressure can be mini-
mized by a phase shift between 20% and 50%.
As opposed to previous work,15 our study design enabled
the analysis of myocardial wall stress. To achieve maximal
unloading, a VAD should be operated such that LV wall
stress is reduced. For the phase shifts 0%, 80%, and
90%, mean wall stress cannot be reduced compared with
baseline; in addition, the phase shifts 80% and 90% lead
to significantly elevated peak wall stress compared with
baseline. These settings should be avoided in patientsrdiovascular Surgery c Volume 146, Number 3 715
FIGURE 5. Boxplots of analyzed variables clustered according to their
phase shift are shown (each box represents the median value and 25th
and 75th percentiles; þ denotes outliers). Panels A through D show
pump flow, flow through the aortic valve, assistance ratio, and regurgitation
to the left ventricle. Data points are normalized by the median values of the
individual data sets because at baseline the pump is turned off.
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of the ventricle.
Furthermore, another potential practical benefit can be
derived from phase shift control: In the potential setting
of weaning the ventricular assistance during recovery, the
load can be adjusted to a level equal to baseline, which
means that the LV is performing the same amount of work
as if the VAD would not be present. This can also be used716 The Journal of Thoracic and Cardiovascular Surgto intermittently assess LV contractility and contractile re-
serve safely, whereas current methods require that the level
of support is reduced or the pump is turned off, thereby in-
creasing the risk of thrombus formation.
To resume the potential clinical implications of our find-
ings, it can be concluded that pulsatile VADs with
ventriculo-aortic cannulation and in synchronized mode
should be operated at a phase shift of approximately 10%
to benefit from the reduced LV stroke work and regurgita-
tion, limited wall stress, reduced end-diastolic volume,
and reduced mean left atrial pressure.
The main limitation of the data presented is that measure-
ments were performed in healthy animals. Nevertheless, the
results presented show a repeatable behavior over several
animals even with strongly varying baseline hemodynamic
conditions. The conclusions of this study may not be di-
rectly applicable to the case of heart failure and need further
research. Furthermore, in a real clinical setting, arrhythmias
and changing hemodynamic conditions would directly alter
the effects of phase shift control or even make this tool use-
less. As an alternative to changing phase shift, a reloading of
the supported LV could be achieved by a reduction of the
stroke volume as proposed by Slaughter and colleagues.11
In clinical practice, no synchrony between the LVand the
pulsatile VAD occurs13,14 because ECG synchronization
was abandoned. This mode was not used because no
satisfactory solution regarding arrhythmia handling was
available and mobility of the patients was limited because
of ECG monitors and wiring. Phase shift varies from beat
to beat, permitting hemodynamically undesirable
situations in accordance with the results presented.
Studies with short phases of device deactivation and with
the pulsatile VAD running have been analyzed.14,25 It can
be speculated that alternately unloading and overloading
the LV in terms of stroke work adversely affects
a potential reverse remodeling process.CONCLUSIONS
The use of ECG synchronization in pulsatile LVADsmight
add substantial benefits in the treatment of this patient group.
Ourfindings suggest that phase shift could beusedas a param-
eter tominimize the load of the heart and to avoid overloading
situations. We also demonstrated that phase shift could serve
for a gradual increase of the stroke work and thereby fine ad-
aptation of the LV load. This method may be important for
strategies aiming at myocardial recovery.
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